10-K
Annual Report
20/20 BIOLABS, INC.
AIDX
NASDAQ
CIK: 1139685
File #: 001-43128
Balance Sheet
52 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
Current assets: | ||
Cash and cash equivalents | 1,025,987 | 1,784,009 |
Accounts receivable, net | 199,954 | 135,272 |
Inventory | 116,217 | 47,164 |
Prepaid expenses and other current assets | 128,975 | 67,780 |
Total current assets | 1,471,133 | 2,034,225 |
License agreement, net | 271,143 | 293,643 |
Property and equipment, net | 56,677 | 116,669 |
Intangible assets, net | 202,264 | 205,529 |
Right-of-use asset, net | 605,289 | 772,385 |
Deferred offering costs | 1,507,794 | — |
Other assets | 23,057 | 161,957 |
Total assets | 4,137,357 | 3,584,408 |
Current liabilities: | ||
Accounts payable | 868,545 | 372,303 |
Accrued liabilities | 785,784 | 346,622 |
Deferred revenue | 414,871 | 470,451 |
Derivative liability | 143,382 | — |
Convertible note | 74,611 | — |
Operating lease liability – current | 175,948 | 165,702 |
Total current liabilities | 2,463,141 | 1,355,078 |
Long-term liabilities: | ||
Convertible notes payable, net | 619,355 | — |
Secured Convertible Promissory Notes | 295,000 | — |
Deferred revenue – long-term | 41,816 | 50,000 |
Derivative liabilities – long-term | 543,545 | — |
Operating lease liability – long term | 488,725 | 673,848 |
Total long-term liabilities | 1,693,441 | 723,848 |
Total liabilities | 4,156,582 | 2,078,926 |
Stockholders’ equity: | ||
Series D | 1,016 | 624 |
Series C | 12,040 | 12,040 |
Series B | 14,715 | 14,715 |
Series A-2 | 4,424 | 4,424 |
Series A-1 | 6,515 | 6,515 |
Series A | 8,464 | 8,464 |
Common stock, $0.01 par value; 50,000,000 authorized; 5,442,249 and 4,823,125 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 54,422 | 48,231 |
Subscription receivable | — | 28,734 |
Additional paid-in capital | 33,126,398 | 30,947,601 |
Accumulated deficit | (33,247,219) | (29,508,398) |
Total stockholders’ (deficit) equity | (19,225) | 1,505,482 |
Series D - Preferred Stock | 1,016 | 624 |
Series C - Preferred Stock | 12,040 | 12,040 |
Series B - Preferred Stock | 14,715 | 14,715 |
Series A-2 - Preferred Stock | 4,424 | 4,424 |
Series A-1 - Preferred Stock | 6,515 | 6,515 |
Series A - Preferred Stock | 8,464 | 8,464 |
Common Stock | 54,422 | 48,231 |
Additional Paid-in Capital | 33,126,398 | 30,947,601 |
Subscription Receivable | — | (28,734) |
Accumulated Deficit | (33,247,219) | (29,508,398) |
Total liabilities and stockholders’ equity | 4,137,357 | 3,584,408 |